In one paragraphObservational study in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
32 authors.
Gaspar Aspas RequenaMontpellier University Hospital, Service d'Hématologie Clinique, Montpellier, France.ORCID 0000-0001-9033-575X Emilie BérardDepartment of Clinical Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France.ORCID 0000-0003-2451-5271 Sarah BertoliToulouse University Hospital, Institut Universitaire du Cancer de Toulouse-Oncopole, Service d'Hématologie, Université de Toulouse, Toulouse, France.ORCID 0000-0003-1084-2781 Rebeca Rodríguez-VeigaHospital Universitario y Politécnico La Fe, Servicio de Hematología, Valencia, Spain.ORCID 0000-0003-2139-8540 Celestine SimandInstitut de Cancérologie Strasbourg Europe (ICANS), Département d'Hématologie, Strasbourg, France.
Mar TormoHospital Clínico Universitario de Valencia, Servicio de Hematología, Biomedical Research Institute INCLIVA, Valencia, Spain.ORCID 0000-0001-9622-1649 Rudy BirsenService d'Hématologie Clinique, Hôpital Cochin-Port Royal (AP-HP), Institut Cochin, Université Paris Cité, Paris, France.ORCID 0000-0001-9696-870X Emmanuelle TavernierCentre Hospitalier Universitaire de Saint-Étienne, Service d'Hématologie Clinique et Thérapie Cellulaire, Saint-Étienne, France.ORCID 0000-0002-1447-8721 Teresa Bernal Del CastilloHospital Universitario Central de Asturias, Servicio de Hematología, Oviedo, Spain.
Martin CarréCentre Hospitalier Universitaire Grenoble-Alpes, Service d'Hématologie, Grenoble, France.ORCID 0000-0001-5834-7654 Cristina GilHospital General Universitario de Alicante, Servicio de Hematología, Alicante, Spain.
Adrien ContejeanCentre Hospitalier Annecy Genevois, Service d'Hématologie Clinique, Epagny Metz-Tessy (Annecy), France.
Eduardo Rodríguez-ArbolíHospital Universitario Virgen del Rocío, Servicio de Hematología, Instituto de Biomedicina de Sevilla (IBiS/CSIC), University of Seville, Seville, Spain.ORCID 0000-0002-2237-6733 Carlos Rodríguez-MedinaHospital Universitario de Gran Canaria Dr. Negrín, Servicio de Hematología, Las Palmas de Gran Canaria, Spain.ORCID 0009-0007-8891-5262 Lauren VeroneseCentre Hospitalier Universitaire de Clermont-Ferrand, Service de Cytogénétique, Clermont-Ferrand, France.ORCID 0000-0002-4414-7974 Eric DelabesseToulouse University Hospital, Institut Universitaire du Cancer de Toulouse-Oncopole, Laboratoire d'Hématologie, Toulouse, France.ORCID 0000-0002-0928-0753 Josefina SerranoHospital Universitario Reina Sofía, IMIBIC, Universidad de Córdoba (UCO), Servicio de Hematología y Hemoterapia, Córdoba, Spain.
Ariane MineurCentre Hospitalier Universitaire de Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France.ORCID 0009-0007-7982-641X María García-FortesHospital Universitario Virgen de la Victoria, Servicio de Hematología, Málaga, Spain.ORCID 0000-0002-0959-9449 Romain GuiezeCentre Hospitalier Universitaire de Clermont-Ferrand, Service d'Hématologie Clinique et de Thérapie Cellulaire, Clermont-Ferrand, France.ORCID 0000-0001-7563-580X Maria Luz AmigoHospital Morales Meseguer, Servicio de Hematología, Murcia, Spain.
Arnaud PigneuxCentre Hospitalier Universitaire de Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France.
Lorenzo Algarra AlgarraHospital General Universitario de Albacete, Servicio de Hematología, Albacete, Spain.ORCID 0000-0002-2527-824X Christian RecherToulouse University Hospital, Institut Universitaire du Cancer de Toulouse-Oncopole, Service d'Hématologie, Université de Toulouse, Toulouse, France.ORCID 0000-0002-3332-4525 Pierre-Yves DumasCentre Hospitalier Universitaire de Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, Bordeaux, France.ORCID 0000-0003-0119-3548 David Martínez-CuadrónHospital Universitario y Politécnico La Fe, Servicio de Hematología, Valencia, Spain.ORCID 0000-0001-7540-4091 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
The addition of midostaurin (MIDO) to intensive chemotherapy (IC) improves survival in younger adults with FLT3-mutated acute myeloid leukemia (AML); however, real-world data in elderly patients (≥ 60 years) are limited. This large, retrospective, multicenter study from three European registries (PETHEMA, FILO, DATAML) evaluated MIDO+IC (n = 194) versus IC alone (n = 371) in 565 patients with FLT3-mutated AML aged ≥ 60 years (median age 67.5 years; 35.6% ≥ 70 years). MIDO+IC was associated with lower day-60 early death (8.2% vs. 21.4%, p < 0.0001) and higher composite complete remission (CRc) rates (78.9% vs. 63.1%, p < 0.0001). After a median follow-up of 46.0 months, median overall survival (OS) was 24.2 months for MIDO+IC versus 8.7 months for IC (p < 0.0001), with 5-year OS rates of 40.6% vs. 12.9%, respectively. Event-free survival (EFS; median 13.5 vs. 4.6 months; 5-year EFS: 36.0% vs. 10.1%) and relapse-free survival (RFS; median 20.2 vs. 8.0 months; 5-year RFS: 45.4% vs. 15.7%) were also significantly improved (both p < 0.0001). The 5-year cumulative incidence of relapse was lower with MIDO+IC (47.8% vs. 67.1%, p < 0.001). In multivariate analyses, midostaurin was an independent favorable prognostic factor for CRc (aOR 1.97 [95% CI: 1.29-2.98]), OS (aHR 0.46 [95% CI: 0.36-0.58]), EFS (aHR 0.49 [95% CI: 0.39-0.60]), and RFS (aHR 0.47 [CI: 0.36-0.62]) (all p ≤ 0.002). These benefits were confirmed by propensity score matching. This large real-world study demonstrates that combining midostaurin with IC significantly improves remission rates and survival outcomes in elderly patients with FLT3-mutated AML, supporting its consideration in this population.
Indexed as
Antineoplastic Combined Chemotherapy Protocolsfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteMutationStaurosporineAgedAged, 80 and overDisease-Free SurvivalFemaleHumansMaleMiddle AgedRegistriesRetrospective StudiesSurvival RateFLT3 protein, humanfms-Like Tyrosine Kinase 3midostaurinStaurosporineelderly patientsFLT3‐mutated AMLintensive chemotherapymidostaurinreal‐world data
Identifiers
PMID41671383
PMCPMC13055135
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390